BriaCell Therapeutics Corp. Common Shares | TalkMarkets

Latest Posts

BriaCell: An Emerging Immuno-Oncology Company

Article By: Bio Deep Dives

Monday, August 14, 2023 11:24 AM EDT

BriaCell has recently announced agreement with the FDA for their pivotal, registration trial in advanced metastatic breast cancer.

In this article: BCTX

Read

Another BriaCell Therapeutics Goal: A Better Treatment For Prostate Cancer

Article By: Lorimer Wilson

Thursday, February 9, 2023 1:13 AM EDT

A look at BriaCell's research into a better treatment for prostate cancer.

In this article: BCTX

Read

BriaCell Therapeutics' Mission: Destroy Breast Cancer

Article By: Lorimer Wilson

Wednesday, January 18, 2023 9:59 AM EDT

BriaCell would make a great buy and hold investment. If, and when, it brings a product directly to market, or is acquired by a major pharmaceutical company, its stock price should go up dramatically.

In this article: WWWW, BCTX, BCTXW Also: INCY

Read

BriaCell Announces Positive End Of Phase II Meeting With The FDA For Bria-IMT(TM) Combination In Advanced Metastatic Breast Cancer

Article By: TalkMarkets Newswire

Wednesday, January 18, 2023 8:56 AM EDT

Registration study success could lead to a Biologics License Application (BLA) submission and commercialization approvals for BriaCell’s novel immunotherapy approach.

In this article: WWW, BCTX, BCTXW

Read

One-On-One With BriaCell Therapeutics Corp. Management

Article By: Kate Hayden

Thursday, October 27, 2022 12:18 PM EDT

BriaCell's lead candidate is Bria-IMT, a whole-cell cancer immunotherapy, combined with Incyte’s retifanlimab, for advanced breast cancer. We asked BriaCell’s CEO, William Williams, about the rationale for the combination.

In this article: WWWW, BCTX, BCTXW, INCY

Read

All Posts